Clinical medicine Press Release
|06/22/2020 - 14:16||
Study led by City of Hope, TGen shows new way of identifying tumor response to immunotherapy
DUARTE, Calif. — Scientists at City of Hope, working in collaboration with researchers at Translational Genomics Research Institute (TGen) and other colleagues across the country, have found that the actions of circulating immune cells — namely how they differentiate and signal — at the start of immunotherapy treatment for cancer can inform how a patient will respond to the therapy. The team’s findings will publish this week in the Proceedings of the National Academy of Sciences of the United States of America.
|City of Hope Na...|
|06/22/2020 - 12:24||
DelMar Pharmaceuticals Presents Positive Interim Data on VAL-083 Demonstrating Favorable Outcomes in Both Newly- Diagnosed and Recurrent GBM at the AACR Virtual Annual Meeting II
DelMar previously announced its invitation from GCAR to participate in the selective GBM AGILE study. This pivotal study, with its robust trial design, industry leading partners, and strong regulatory endorsement, is intended to serve as the basis for VAL-083's new drug application (NDA) submission and registration.
|06/22/2020 - 11:33||
UPMC and VA Pittsburgh Partner to Perform VAs First LDLT
PITTSBURGH – VA Pittsburgh Healthcare System (VAPHS) and UPMC partnered to perform VA’s first living-donor liver transplant, in which a portion of a healthy person’s liver is transplanted to someone in need of a liver.
|06/21/2020 - 19:40||
Transplant Therapeutics Consortium Receives Acceptance of Letter-of-Intent for iBox Scoring System as a Reasonably Likely Surrogate Endpoint from the Biomarker Qualification Program
CARY, N.C. , June 22, 2020 / / -- Critical Path Institute (C-Path) announced Wednesday, June 17, that its Transplant Therapeutics Consortium (TTC), of which Veloxis Pharmaceuticals is a member, has received a positive response to its Letter of Intent (LOI) from the U.S. Food and Drug Administration (FDA) detailing the decision to accept the iBox Scoring System into the Center for Drug Evaluation and Research (CDER) Biomarker Qualification Program (BQP).
|06/20/2020 - 15:15||
IDPH Investigating Increase In Foodborne Illnesses
SPRINGFIELD – The Illinois Department of Public Health (IDPH) has received confirmation of approximately 23 cases that appear to be linked to a multi-state outbreak of cyclosporiasis, an intestinal illness caused by the microscopic Cyclospora parasite. Cases have been reported in counties across Illinois with people becoming ill starting in mid-May. The initial investigation indicates a link to consumption of store brand packaged garden salads from Aldi, Hy-Vee, and Jewel-Osco grocery stores in Illinois.
|06/19/2020 - 10:22||
Macomb County Fathers Celebrate Fathers Day While Being Treated for Brain Cancer
DETROIT – Father’s Day is special for all dads, but even more so for two Macomb county fathers who will celebrate while being treated for brain cancer – something they do almost all the time. Dr. Robert Gryebet of Macomb, 63, and Andrew Tobin of St.
|Henry Ford Heal...|
|06/19/2020 - 08:24||
Breaking the monopoly of imported anti-HER2 monoclonal antibody drugs Approval obtained for Inetetamab, the first innovative anti-HER2 monoclonal antibody independently developed in China
The first approved indication of Cipterbin® is for the treatment of HER2-positive metastatic breast cancer combining with chemotherapy.
|06/18/2020 - 12:33||
Study: IBS Patients with a History of Cannabis Use Have Fewer Hospitalization Costs
Chicago, IL: Cannabis use is associated with a decrease in inpatient healthcare utilization in subjects with irritable bowel syndrome (IBS), according to data published in the journal Cureus .
|06/17/2020 - 14:57||
Piedmont Henry Launches Robotic Assisted Procedures
Stockbridge, Ga. (June 17, 2020) Starting June 18, 2020, for the first time, Piedmont Henry Hospital will offer numerous robotic assisted surgical procedures. Robotically assisted surgery enhances the surgeon’s vision and control, and in some cases can lead to faster recovery times and better clinical outcomes for patients. By using robotics, surgeons can make smaller incisions and do intricate work in certain very complex procedures.
|Piedmont Henry ...|
|06/17/2020 - 06:58||
Accuray Launches New CyberKnife S7 System
SUNNYVALE, Calif. , June 17, 2020 / / -- Accuray Incorporated (NASDAQ: ARAY) announced today the company has launched the CyberKnife ® S7™ System , an innovative device combining speed, advanced precision, and real-time artificial intelligence (AI)-driven motion tracking and synchronization treatment delivery for all stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments — in as little as 15 minutes.
|06/16/2020 - 15:10||
Registration Opens for the Virtual ADCES 2020 Annual Conference
The Association of Diabetes Care & Education Specialists (ADCES) 2020 Annual Conference has gone virtual. The online conference will take place Thursday, Aug.
|06/16/2020 - 09:34||
Wearable patch may provide new treatment option for skin cancer
Chi Hwan Lee, a Purdue engineering innovator, developed a wearable patch to provide a new treatment option for skin cancer.
|06/15/2020 - 15:18||
New Findings from Groundbreaking Study Shows Extended Delay in Onset of Type 1 Diabetes
NEW YORK – June 15, 2020— Emily Sims, M.D. today shared new findings that a breakthrough drug significantly delays the onset of type 1 diabetes (T1D).
|06/15/2020 - 09:52||
Multilevel Interventions Improve HPV Vaccination Rates of Series Initiation and Completionation and Completion
BOSTON - New research from Boston Medical Center shows that providing education and training to pediatric and family medicine providers about the importance of human papillomavirus (HPV) vaccines, in tandem with healthcare systems changes including starting an HPV vaccination series before the age of 11, improves the overall rate of HPV vaccinations among adolescent patients.
|Boston Medical ...|
|06/15/2020 - 05:22||
Bellicum Receives FDA IND Clearance to Initiate a Phase 1/2 Clinical Trial for BPX-603, a Dual-Switch GoCAR-T for HER2+ Solid Tumors
BPX-603 is a GoCAR-T ® product candidate targeting solid tumors that express human epidermal growth factor receptor 2 (HER2). BPX-603 is the company’s first dual-switch GoCAR-T ® product candidate, which incorporates both the company’s iMC activation and CaspaCIDe ® safety switch technologies.
|06/15/2020 - 00:41||
If You Feel Apprehensive and Hopeless Resulting from Insomnia Take Lorazepam for Sleep - Best Sleeping Tablets
After a spate of insomnia, it feels like the mind has been lost. Deal with the shocking diagnosis as well as keep house and home together and it took a toll on health and ability to get enough restorative sleep. Lorazepam 2mg helped to sleep and to deal with anxiety. - Best Sleeping Tablets
|Best Sleeping T...|
|06/12/2020 - 18:04||
One in Three People with Diabetes Do Not Receive Support Needed to Deal with Emotional Aspects of Living with Diabetes
Denmark study of self-reported data from more than 9,000 people finds overall need for better access to psychological and other non-medical diabetes care for people living with diabetes and their caregivers Results presented today at the American Diabetes Association’s ® (ADA’s) 80th Virtual Scientific Sessions show 18% of people living with diabetes in Denmark needed a referral for a psychologist but had not been offered one, and 36% said they did not receive the support they needed to cope with their emotions related to diabetes.
|06/12/2020 - 03:08||
Aspirin reduces long-term colorectal cancer risk in genetically predisposed individuals
Long-term results of an international multi-center trial CaPP2 showed that 600 mg of aspirin daily reduced colorectal cancer risk by half compared to those on placebo. Eight hundred and sixty-one genetically susceptible patients were randomized to have either aspirin or placebo for 2–4 years and followed up for 10–20 years. Of those on aspirin, 40 had colorectal cancer, while 58 of those on placebo got colorectal cancer during follow-up.
|06/11/2020 - 17:11||
Two new, powerful small molecules may be able to kill cancers that other therapies cant
DUARTE, Calif. — City of Hope scientists have identified and developed two potent small molecules that appear to suppress tumor growth in multiple cancers even when other treatments cease to work, possibly due to the development of drug resistance.
|City of Hope Na...|
|06/11/2020 - 09:52||
Alstom, Decathlon and a consortium of companies donate 200 adapted snorkel masks as tools to combat the COVID-19
French transport and sports companies have joined forces, together with other actors, to deliver protections to different hospitals in Mexico, in order to face the health crisis caused by COVID-19
|06/11/2020 - 05:06||
Recent Research And New Multidisciplinary Framework For Genetic Testing In Prostate Cancer Supports Broader Use Of Panels, Testing In Early Stage Disease
SAN FRANCISCO, June 11, 2020 / / -- New recommendations from a large, multidisciplinary consensus conference published this week in the Journal of Clinical Oncology suggest expanding use of genetic testing to guide treatment for men with prostate cancer, including the use of panel testing and testing patients with early stage disease. Taken together with research recently presented by Invitae (NYSE: NVTA), a leading genetics company, the publications underscore the utility of increased access to genetic testing for men with prostate cancer across all stages of disease.
|06/11/2020 - 04:11||
City of Hope signs licensing agreement with Scopus BioPharma Inc. to develop novel, targeted immuno-oncology gene therapy
DUARTE, Calif. — City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, has signed an exclusive, worldwide licensing agreement with Scopus BioPharma Inc., a biopharmaceutical company focused on novel therapeutics for serious diseases with significant unmet medical needs. Scopus will further develop and plans to commercialize a City of Hope first-in-class, targeted immuno-oncology gene therapy.
|City of Hope Na...|
|06/11/2020 - 03:55||
Rigel to Present Poster Highlighting TAVALISSE at the Virtual Edition of the 25th European Hematology Association (EHA) Annual Congress
SOUTH SAN FRANCISCO, Calif., June 11, 2020 / / -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that data related to TAVALISSE ® (fostamatinib disodium hexahydrate) tablets will be highlighted in a presentation at the Virtual Edition of the 25 th EHA Annual Congress taking place June 11-21, 2020. The presentation will be made available on the event's website at www.ehaweb.org/congress/ on Friday, June 12 at 8:30 am CEST.
|06/10/2020 - 04:19||
PerkinElmer Launches Pre-eclampsia Kit for Enhanced Management
This kit will enable short term prediction of pre-eclampsia and aid in diagnosis in the second and third trimesters of pregnancy together with the previously launched DELFIA® Xpress PlGF 1-2-3™ assay . It is easily adaptable for current screening customers using the DELFIA® Xpress instrument.
|06/09/2020 - 14:39||
City of Hope scientists showcase new findings at the 2020 AACR Virtual Annual Meeting II
DUARTE, Calif. — City of Hope scientists will showcase research at the AACR Virtual Annual Meeting II that could one day lead to real-time diagnostic imaging and leading-edge genomic profiling that improve health outcomes for cancer patients, and much more.
|City of Hope Na...|